article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.

article thumbnail

Biotech startup pulls in $187M to make ‘multi-payload’ ADCs

BioPharma Drive: Drug Pricing

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.

Licensing 250
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs

BioPharma Drive: Drug Pricing

Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead. A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study.

article thumbnail

Treatments for poxviruses -- including those causing mpox and smallpox -- may already exist in licensed drugs

Science Daily: Pharmacology News

Tecovirimat is an anti-poxviral drug, and its use is driving the emergence of drug-resistant variants of the monkeypox virus. Existing drugs -- developed to treat other viral infections -- also target this cellular protein.

Licensing 172
article thumbnail

Merck moves into obesity with deal for Hansoh’s GLP-1 pill

BioPharma Drive: Drug Pricing

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.

Licensing 157
article thumbnail

Recursion’s Chris Gibson on AI in biotech, competition and ‘virtuous cycles’

BioPharma Drive: Drug Pricing

Showing reporters and industry veterans a demonstration of its new drug development software, Recursion said at J.P. Morgan it is now licensing its work to buyers.

Licensing 167
article thumbnail

Nobel Prize celebrates AI’s role in protein structure innovation

Drug Target Review

Baker’s model could revolutionise drug development, synthetic biology, and nanotechnology, opening possibilities for new medical treatments, vaccines, nanomaterials, and sensors.